Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Long-Term Outcomes of Vedolizumab and TNF Inhibitors in Patients with Ulcerative Colitis

  • By

  • Siddharth Singh

  • Jonas Söderling

  • Anders Forss

  • Mathias Rask-Andersen

  • Jonas Halfvarson

  • Åsa H. Everhov

  • Jonas F. Ludvigsson

  • Ola Olén

  • SWIBREG study group

  • Malin Olsson

  • Pär Myrelid

  • Henrik Hjortswang

  • Jonas Bengtsson

  • Hans Strid

  • Marie Andersson

  • Susanna Jäghult

  • Caroline Nordenvall

  • Charlotte Hedin

  • Martin Rejler

  • Olof Grip

  • Ulrika L Fagerberg

  • Karl Mårild

  • Johann Hreinsson

  • Pontus Karling

  • September 25, 2026

Share

Clinical Report: Comparative Long-Term Outcomes of Vedolizumab and TNF Inhibitors

Overview

This study evaluates long-term outcomes in biologic-naive patients with ulcerative colitis (UC) who initiated treatment with either vedolizumab or TNF inhibitors (infliximab or adalimumab).

Background

Ulcerative colitis (UC) management has evolved with the introduction of advanced therapies, including TNF antagonists and vedolizumab. This study addresses the gap in knowledge regarding the long-term effectiveness of these therapies in a real-world setting.

Data Highlights

No numerical data was provided in the source material.

Key Findings

  • Vedolizumab and TNF inhibitors are commonly used advanced therapies for UC.
  • Previous studies indicate similar effectiveness between infliximab and vedolizumab in short-term outcomes.
  • The VARSITY trial showed higher remission rates for vedolizumab compared to adalimumab at one year.
  • Long-term outcomes after treatment failure or switching therapies are not well understood.
  • This study utilized a nationwide cohort to assess long-term outcomes in biologic-naive patients.

Clinical Implications

Clinicians should consider the long-term implications of treatment strategies for UC, as the choice between vedolizumab and TNF inhibitors may affect hospitalization and surgery rates. Ongoing evaluation of patient outcomes is essential for informed treatment decisions.

Conclusion

This study highlights the importance of evaluating long-term outcomes in UC treatment strategies, emphasizing the need for further research to guide clinical practice.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Journal of Crohn's and Colitis — Tofacitinib Versus Vedolizumab Among Bio-naive Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
  3. The New Gastroenterologist — Impact of Previous TNF Antagonist Treatment on the Effectiveness of Advanced Ulcerative Colitis Therapies
  4. Journal of Crohn's and Colitis — Clinical Outcomes After First-Line Anti- Tumor-Necrosis-Factor Treatment of Patients With Inflammatory Bowel Disease—A Prospective Multicenter Cohort Study
  5. The New Gastroenterologist — Impact of Prior Anti-TNF Treatment on the Effectiveness of Subsequent Ulcerative Colitis Therapies
  6. Guideline Highlights for Ulcerative Colitis
  7. Impact of Previous TNF Antagonist Treatment on the Effectiveness of Advanced Ulcerative Colitis Therapies
  8. Tofacitinib Versus Vedolizumab Among Bio-naive Patients With Ulcerative Colitis
  9. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis | New England Journal of Medicine
  10. Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis | Gastroenterology and Hepatology | JAMA Network Open | JAMA Network

Original Source(s)

Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis

  • by Siddharth Singh, Jonas Söderling, Anders Forss, Mathias Rask-Andersen, Jonas Halfvarson, Åsa H. Everhov, Jonas F. Ludvigsson, Ola Olén, SWIBREG study group, Malin Olsson, Pär Myrelid, Henrik Hjortswang, Jonas Bengtsson, Hans Strid, Marie Andersson, Susanna Jäghult, Caroline Nordenvall, Charlotte Hedin, Martin Rejler, Olof Grip, Ulrika L Fagerberg, Karl Mårild, Johann Hreinsson, Pontus Karling

  • September 25, 2026

Related Content

5.0 T versus 1.5 T and 3.0 T upper abdominal MRI: a prospective two‑cohort study of image quality and diagnostic confidence

Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy

Evolution of Discourse in the Reddit Hemorrhoid Community: Topic and Sentiment Analysis